The U.S. Food and Drug Administration (FDA) has expanded the treatment window for use of medical device company Concentric Medical's Trevo image-guided clot retrieval device for stroke patients.
The device is used as an initial therapy for stroke to reduce paralysis, speech difficulties, and other stroke-related disabilities. Previously, it was cleared for use six hours after the onset of symptoms; the FDA has now expanded this to 24 hours.
Trevo is inserted through a catheter into the blood vessel to the site of the blood clot. A section at the end of the device expands up to 6 mm and grips the clot, allowing the physician to remove it by pulling it back through the blood vessel, the FDA said.
![Representative example of a 16-year-old male patient with underlying X-linked adrenoleukodystrophy. (A, B) Paired anteroposterior (AP) chest radiograph and dual-energy x-ray absorptiometry (DXA) report shows lumbar spine (L1 through L4) areal bone mineral density (BMD). The DXA report was reformatted for anonymization and improved readability. The patient had low BMD (Z score ≤ −2.0). (C) Model (chest radiography [CXR]–BMD) output shows the predicted raw BMD and Z score in comparison with the DXA reference standard, together with interpretability analyses using Shapley additive explanations (SHAP) and gradient-weighted class activation maps. The patient was classified as having low BMD, consistent with the reference standard. AM = age-matched, DEXA = dual-energy x-ray absorptiometry, RM2 = room 2, SNUH = Seoul National University Hospital, YA = young adult.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/ai-children-bone-density.0snnf2EJjr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
